Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report

BACKGROUND Hepatosplenic T-cell lymphoma(HSTCL)is a rare subtype of non-Hodgkin’s lymphoma,which has an aggressive clinical course and an extremely poor prognosis.Chidamide is a novel,orally active,benzamide-type histone deacetylase(HDAC)inhibitor that has been used for peripheral T-cell lymphoma(PTCL)treatment.However,to date,there has been no report of the treatment and effect of the HDAC inhibitor chidamide in HSTCL,which is a special subtype of PTCL.CASE SUMMARY A 45-year-old male patient was admitted with splenomegaly and slight bicytopenia.He was diagnosed with HSTCL via splenectomy.The patient was treated with fractionated cyclophosphamide,vincristine,doxorubicin,and dexamethasone alternating with high-dose methotrexate and cytarabine regiment as inductive therapy.Unfortunately,the disease progressed rapidly during chemotherapy before a suitable allogeneic gene transplant donor was found.The chidamide-combined chemotherapy regimen and single-drug oral maintenance regimen achieved complete remission,duration of response of 9 mo,and overall survival of 15 mo.CONCLUSION The novel agent chidamide can be used in HSTCL to achieve deep remission and improve the duration of response and overall survival.

Etoposide,dexamethasone,and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma:A randomized phase III study

Methotrexate,etoposide,dexamethasone,and pegaspargase(MESA)with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma,nasal type(NKTCL).We explored the efficacy and safety of reduced-intensity,non-intravenous etoposide,dexamethasone,and pegaspargase(ESA)with sandwiched radiotherapy.This multicenter,randomized,phase III trial enrolled patients aged between 14 and 70 years with newly diagnosed early-stage nasal NKTCL from 27 centers in China.Patients were randomly assigned(1:1)to receive ESA(pegaspargase 2,500 IU/m^(2)intramuscularly on day 1,etoposide 200 mg orally,and dexamethasone 40 mg orally on days 2–4)or MESA(methotrexate 1 g/m^(2)intravenously on day 1,etoposide 200 mg orally,and dexamethasone 40 mg orally on days 2–4,and pegaspargase 2,500 IU/m^(2)intramuscularly on day 5)regimen(four cycles),combined with sandwiched radiotherapy.

Dendritic Cell-Derived Exosomes Stimulate Stronger CD8^+ CTL Responses and Antitumor Immunity than TVimor Cell-Derived Exosomes

从树枝状的细胞(DC ) 和肿瘤细胞导出的 Exosomes (EXO ) 被用来在动物模型并且在临床的试用刺激 antitumor 免疫者回答。然而，有不，一起， antitumor 免疫者回答的 stimulatory 效率的比较由这二支通常使用的 EXO 疫苗导致了。在这研究，我们选择了房间表示学习 EXO 的特征从一个 transfected EG7 肿瘤导出的显型 ovalbumin (卵) 和由流动 cytometry 的搏动卵的 DC。我们在在 EXO 的这二种类型之间的卵特定的有免疫力的回答的正式就职比较了 stimulatory 效果。我们发现卵搏动蛋白质的导出 DCovA 的 EXO (EXODC ) 能更高效地在 vivo 刺激天真的卵特定的 CD8+ T 房间增长和区别进细胞毒素的 T 淋巴细胞，并且比 EG7 肿瘤导致更有效的 antitumor 免疫导出房间的 EXO (EXOEG7 ) 。另外，我们阐明了在 EXO 的 stimulatory 效果被主人 DC 送到 T 房间回答的 EXO 疫苗的主人 DC 的重要角色。因此，导出 DC 的 EXO 可以在 antitumor 免疫的正式就职代表一支更有效的基于 EXO 的疫苗。

Third-party relational governance and collaborative innovation performance:The role of IPR protection

The purpose of this study is to explore the impact of third-party relational governance on the performance of collaborative innovation in China. By integrating the relational view and innovation appropriation perspectives, this study analyses the effects of three mechanisms of third-party relational governancedco-reputation, interorganizational routines, and technological normsdon collaborative innovation performance. Additionally,this study investigates the moderating effects of the protection of intellectual Property Rights(IPR) on the relationship between third-party relational governance and collaborative innovation performance. Survey data of high-technology firms in China are used to empirically test the hypotheses. The results show that third-party relational governance has a positive effect on collaborative innovation performance and that IPR protection has different moderating effects. This study contributes to the relational governance literature by adding the perspective of third parties and analyzing three mechanisms of third-party relational governance in a single model. This study also contributes to the innovation appropriation literature by examining the role of IPR protection in governing collaborative innovation in China. Finally, this study offers suggestions on how Chinese firms should govern their collaborative innovation to remedy the limitations of a weak IPR legal institutional framework.

Mechanical Design with Experimental Verification of a Lightweight Exoskeleton Chair

In this study,a human-chair model was developed as the basis for a wearable-chair design.A prototype chair,HUST-EC,based on the model was fabricated and evaluated.Employing the optimization under the golden divisional method,an optimized simulation of the operating mode with the lowest chair height was implemented.A novel multi-link support structure has been established with parameters optimized using Matlab software.The stress analysis of the solid models was conducted to ensure the adequate support from the designed chair for the user.Ten subjects participated in the evaluation experiment,who performed both static tasks and dynamic tasks.The experimental results consisted of subjective evaluation and objective evaluation.The experimental data demonstrate that(1)the HUST-EC can effectively reduce the activation level of related muscles at a variety of tasks;(2)the plantar pressure was reduced by 54%–67%;(3)the angle between the upper body and the vertical axis was reduced by 59%–77%;(4)the subjective scores for chair comfortability,portability,and stability were all higher than 7.The results further revealed that the designed chair can reduce the musculoskeletal burden and may improve work efficiency.

Fixed-time constrained acceleration reconstruction scheme for robotic exoskeleton via neural networks

Accurate acceleration acquisition is a critical issue in the robotic exoskeleton system,but it is difficult to directly obtain the acceleration via the existing sensing systems.The existing algorithm-based acceleration acquisition methods put more attention on finite-time convergence and disturbance suppression but ignore the error constraint and initial state irrelevant techniques.To this end,a novel radical bias function neural network(RBFNN)based fixed-time reconstruction scheme with error constraints is designed to realize high-performance acceleration estimation.In this scheme,a novel exponential-type barrier Lyapunov function is proposed to handle the error constraints.It also provides a unified and concise Lyapunov stability-proof template for constrained and non-constrained systems.Moreover,a fractional power sliding mode control law is designed to realize fixed-time convergence,where the convergence time is irrelevant to initial states or external disturbance,and depends only on the chosen parameters.To further enhance observer robustness,an RBFNN with the adaptive weight matrix is proposed to approximate and attenuate the completely unknown disturbances.Numerical simulation and human sub ject experimental results validate the unique properties and practical robustness.